PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Afamelanotide→

Afamelanotide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
75921-69-6
Molecular formula
C78H111N21O19
Molecular weight
1646.8 g/mol
Drug class
Melanocortin-1 receptor (MC1R) agonistsynthetic alpha-melanocyte-stimulating-hormone analogue
Mechanism of action
Activates melanocortin-1 receptors on melanocytes, increasing eumelanin production and skin pigmentation. The additional eumelanin reduces penetration of light into the skin and helps reduce phototoxic reactions in erythropoietic protoporphyria.
Indications / reported uses
  • Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) under the EMA-authorised implant indication; specialist-centre use and product-specific monitoring apply

Sources: EMA EPAR — Scenesse (updated 7 Oct 2026) · EMA product information — Scenesse · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Afamelanotide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Afamelanotide Permitted Daily Exposure (PDE) report (the Afamelanotide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Afamelanotide Occupational Exposure Limit (OEL) report (the Afamelanotide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.